A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
FT576 in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE3
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
DALY II USA/ MB-CART2019.1 for DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Status
- TERMINATED
- Phase
- PHASE3
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
FT819 in Subjects With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2